News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) Weight-Loss Drug Qnexa Gets Three-Month Delay for FDA Review


4/10/2012 7:28:26 AM

Drug developer Vivus Inc. says that regulators will take another three months to review the safety strategy on its proposed obesity drug Qnexa. The company says the Food and Drug Administration is now expected to make a decision on Qnexa by July 17. Previously the agency was scheduled to return a decision by April 17. Vivus says the FDA extended its review because it needed more time to evaluate the risk evaluation and reduction strategy Vivus has proposed.

Read at Yahoo Finance
Read at Washington Post
Read at Fox News
Read at Bloomberg


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES